key: cord-0959713-de3guelz authors: Onishi, Y.; Zarogoulidis, P.; Ji, R-C; Onishi, M.; Kubota, N.; Eshita, Y. title: Consideration with “Intratumoral gene therapy versus intravenous gene therapy for distant metastasis control with DDMC non-viral vector–p53” date: 2021-10-12 journal: Gene Ther DOI: 10.1038/s41434-021-00298-y sha: b45d872e9d74986da932035672ffa54972ae6868 doc_id: 959713 cord_uid: de3guelz nan The ANOVA-Test for three groups are also done as Table 2 , and good results are obtained (P < 0.05). The mean survival should be displayed as intratumoral (17.3 days)> intravenous(15.6 days) >control(13.2 days) after correction. It may be depended on rapid intravenous injection that four mice died earlier after administration containing control. It is difficult for the viral vectors to select multiple-dose because of neutralized antibody with its immunogenicity such as AAV vector. The lipofection reagents are also not suitable to transfect in-vivo for its unstable properties. Results show that the complexes by DDMC/p53 have an excellent anticancer activity for systemic administration by depending on EPR effect [3] and avoidance of RES [4, 5] . Polymer-based drug delivery systems (DDS) are widely used as carriers for targeted drug delivery due to promoting EPR effect and avoidance of RES. DDS technology by transfection reagents (DDMC) [6] in vivo compose of 1. A long retention time in body by control of renal excretion. 2. An antigenicity reducing by reticuloendothelial system (RES). 3. A high protect facility for DNase or RNase degradation. 4. A drug to a target effectively by the enhanced permeation and retention (EPR) effect. DDMC will become the most important DDS technology after the COVID-19 pandemic. 1 Ryujyu Science Corporation, 39-4 Kosora-cho, Seto, Aichi, Japan. 2 Pulmonary-Oncology Department, "General Clinic" Euromedica, Thessaloniki, Greece. 3 Faculty of Welfare and Health Science, Oita University, Oita, Japan. 4 Department of Chemistry, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, Japan. 5 Hokkaido University International Institute for Zoonosis Control, North 20 West 10, Kita-ku, Sapporo, Hokkaido 001-0020, Japan. ✉ email: vyx00545@nifty.com www.nature.com/gt Not a significant outlier (P < 0.05). 1 (b) group is done three times trial till not a significant outlier (P < 0.05). 2 They are deleted four samples of three and seven survival days, statistically. The Smirnov-Grubbs method, which is one of the statistical methods of the rejection of outliers, tried to find outliers. The analysis indicated that an additional one data for (a) and three data for (b) were significant outliers. 3 (c) group does not contain a significant outlier (P < 0.05). Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Intratumoral gene therapy versus intravenous gene therapy for distant metastasis control with 2-diethylaminoethyl-dextran methyl methacrylate copolymer non-viral vector-p53 Procedures for detecting outlying observations in samples A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Large unilamellar liposomes with low uptake into the reticuloendothelial system Tumor accumulation of novel RES-avoiding liposomes Characteristics of 2-diethylaminoethyl(DEAE)-dextran-MMA graft copolymer as a non-viral gene carrier The authors declare no competing interests. Correspondence and requests for materials should be addressed to Y. Onishi.Reprints and permission information is available at http://www.nature.com/reprints